Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 3731579 in Healthy Volunteers (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
Latest Information Update: 31 Dec 2024
Price :
$35 *
At a glance
- Drugs BI 3731579 (Primary) ; Midazolam (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 27 Dec 2024 Status changed from not yet recruiting to recruiting.
- 10 Dec 2024 New trial record
- 06 Dec 2024 Planned End Date changed from 1 May 2025 to 19 May 2025.